Become a Member of the Supporters Guild
…The Supporters Guild is named in memory of Charlie Guild, who lost her battle with melanoma in 2003. When Charlie…
Become a Member of the Supporters Guild
…The Supporters Guild is named in memory of Charlie Guild, who lost her battle with melanoma in 2003. When Charlie…
,
One Survivor Finds Empowerment through Education and Supporting Others
…was, in fact, melanoma. “She told me not to Google it,” she said. “That raised all the red flags.” But Ann…
,
Create a Legacy with AIM
…of AIM at Melanoma, consider a legacy gift in your will today. If you have any further questions about FreeWill…
,
The Importance of Having a Will
It started with a 13-year melanoma survivor letting us know that he had put us in his will. Jeff Berg,…
,
Ways to Give: Workplace Giving
Here at AIM at Melanoma, we are fortunate to be frequently asked an important question: What are the different ways…
,
Ten Years of Pembrolizumab Shows Sustained Results
There is good news for patients with advanced melanoma who received pembrolizumab. Results from a clinical trial after ten years…
,
Fall 2024 Newsletter
…committee Thank you for your continued support in advancing melanoma research. Together, we can make a difference in the fight…
,
Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma
Side Effect Central is a series of articles designed to help patients with melanoma and their caregivers understand the side…
,
Melanoma Legislation: Progress Report
The facts are straightforward: Indoor tanning before 18 years of age increases one’s risk of melanoma by 85%,1 and the…
,
Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
August 24, 2021 Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
,
,
Recent Posts
Jun. 09, 2026
The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026